Top

Published in:

01-06-2009 | Original Article

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review

Authors: Ingo J. Diel, Rudolf Weide, Hubert Köppler, Lucia Antràs, Michael Smith, Jesse Green, Neil Wintfeld, Maureen Neary, Mei Sheng Duh

Published in: Supportive Care in Cancer | Issue 6/2009

Abstract

Purpose

This retrospective study compared renal impairment rates in breast cancer, multiple myeloma, prostate cancer and non-small cell lung cancer patients treated with ibandronate or zoledronic acid.

Study design

Medical records in two German oncology clinics from May 2001 to March 2006 were retrospectively reviewed. Creatinine measurements were analyzed from baseline (before bisphosphonate treatment) to last available measurement for each patient. The Cox proportional hazards model and the Andersen–Gill extension of the Cox model for multiple events analysis were used for multivariate analysis, which controlled for age, clinic site, primary cancer type, baseline SCr or GFR value, prior bisphosphonate use, concomitant use of drugs associated with acute renal failure, and renal-related comorbidities.

Results

Of 333 patients, 109 received ibandronate and 256 received zoledronic acid (32 patients had both drugs). Compared with ibandronate, the zoledronic acid group had a significantly better baseline renal function and fewer patients had a history of renal disease. Zoledronic acid treatment increased the relative risk (RR) and the incidence rate (IR) of renal impairment by ~1.5-fold in all assessed patients (all tumors) compared with ibandronate. Multivariate analysis found significantly higher hazards ratios for zoledronic acid over ibandronate (two to sixfold), after adjusting for differences in characteristics between the two treatment groups.

Conclusions

In this retrospective review, patients were significantly more likely to experience renal impairment with zoledronic acid than with ibandronate.

Berenson J, Hirschberg R (2004) Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 9:319–329PubMedCrossRef

Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M (2006) Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29:534–540 doi:10.1159/000096056 PubMedCrossRef

Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405PubMedCrossRef

Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133–1137PubMedCrossRef

Body JJ, Diel IJ, Tripathy D, Bergström B (2006) Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15:299–302CrossRef

Body JJ, Lichinitser M, Tjulandin S, Bergström B (2006) Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data [abstract 68]. Bone 38(3 Suppl.1):S69

Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676–1679PubMedCrossRef

Chern B, Joseph D, Joshua D et al (2004) Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12:463–466PubMedCrossRef

Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460PubMedCrossRef

10.

Diel IJ, Weide R, Köppler H et al (2006) Renal impairment in cancer patients following zoledronic acid or ibandronate treatment [abstract 1002P]. Ann Oncol 17(Suppl.9):78

11.

Eastell R, Garnero P, Vrijens B et al (2006) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408

12.

Ezra A, Golomb B (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175–195PubMedCrossRef

13.

Green JR, Müller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745–751PubMed

14.

Heidenreich A, Ohlmann C, Olbert P Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1(Suppl.5):S270

15.

Henrich D, Bergner R, Hoffman M et al (2005) Open-label study of ibandronate in elderly myeloma patients with pre-existing renal deterioration [abstract 3459]. Blood 106:11CrossRef

16.

Johnson KB, Gable P, Kaine EM et al (2003) Significant deterioration in renal function with the new bisphosphonate zoledronic acid [abstract 2968]. J Clin Oncol 22(Suppl.):738

17.

Kristensen B, Ejlertsen B, Groenvold M et al (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246:67–64PubMedCrossRef

18.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed

19.

Lyubimova NV, Kushlinsky NE, Lichinister MR Schlosser K (2003) Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin Drug Invest 23:707–716CrossRef

20.

Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567PubMed

21.

Mancini I, Dumon JC Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587–3592PubMedCrossRef

22.

Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289PubMedCrossRef

23.

Mazj S, Lichtman SM (2004) Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics [abstract 8039]. J Clin Oncol 22(Suppl.):735

24.

Mühlbauer RC, Bauss F, Schenk R et al (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003–1011PubMedCrossRef

25.

Munier A, Gras V, Andrejak M et al (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39:1194–1197PubMedCrossRef

26.

Pfister T, Atzpodien E, Bauss F (2003) The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191:159–167PubMedCrossRef

27.

Pfister T, Atzpodien E, Bohrmann B, Bauss F (2005) Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97:374–381PubMedCrossRef

28.

Reginster JY, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415–423PubMedCrossRef

29.

Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744PubMedCrossRef

30.

Taggart H, Bolognese MA, Lindsay R et al (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77:262–270PubMedCrossRef

31.

Thadhani R, Pascual M, Bonventre JV (1996) Acute renal failure. N Engl J Med 334:1448–1460PubMedCrossRef

32.

von Moos R, Caspar CB, Angst R et al (2006) Renal safety of intravenous ibandronate 6 mg infused over 15 minutes or 60 minutes in patients with breast cancer and bone metastases [abstract 1078]

Title: Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review
Authors: Ingo J. Diel
Rudolf Weide
Hubert Köppler
Lucia Antràs
Michael Smith
Jesse Green
Neil Wintfeld
Maureen Neary
Mei Sheng Duh
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 6/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0553-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Study design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

Improve the management of patients with skull bone metastases by means of helical tomotherapy

Indicators of surgery and survival in oncology inpatients requiring surgical evaluation for palliation

Child and parental adaptation to pediatric stem cell transplantation

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine

Fatigue in Brazilian cancer patients, caregivers, and nursing students: a psychometric validation study of the Piper Fatigue Scale-Revised

The palliative performance scale: examining its inter-rater reliability in an outpatient palliative radiation oncology clinic

Keynote webinar | Spotlight on antibody–drug conjugates in cancer